Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Company Deals

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Fineline Cube Jun 16, 2026
Company Deals

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Fineline Cube Jun 16, 2026
Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

Fineline Cube Jun 15, 2026
Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Fineline Cube Jun 16, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Fineline Cube Jun 16, 2026
Company Deals

Sansure Biotech Partners with Hunan Normal University for Research and Talent Development

Fineline Cube Feb 18, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has announced a strategic partnership with...

Company Deals

Amcor Acquires Shanghai-Based MDK to Expand Asia-Pacific Footprint

Fineline Cube Feb 18, 2023

Switzerland-based packaging firm Amcor (NYSE: AMCR) has unveiled the signing of a deal to acquire...

Company Drug

CSPC’s NBL-020 Gets NMPA Approval for Clinical Study in Advanced Solid Tumors

Fineline Cube Feb 17, 2023

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving the go-ahead from the National...

Company Drug

Kelun Pharma’s Generic Jardiance Gains New Indication in China

Fineline Cube Feb 17, 2023

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has obtained another indication approval in China...

Policy / Regulatory

Hangzhou Singclean Stripped of VBP Status for Artificial Lenses

Fineline Cube Feb 17, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has revealed that Hangzhou Singclean Medical Products Co., Ltd...

Company Deals R&D

Topgen Biopharm Partners with Fudan University for Breast Cancer Gene Detection

Fineline Cube Feb 17, 2023

Zhejiang-based tumor precision medicine specialist Topgen Biopharm Co., Ltd has entered into a strategic partnership...

Company Deals Digital

By-Health Partners with Meituan’s Drug Purchase APP for New Retail Expansion

Fineline Cube Feb 17, 2023

China-based By-Health Co., Ltd. (SHE: 300146) has entered into a strategic partnership with Meituan’s drug...

Company Deals

Kangtai Biological Partners with Pakistani Firm for Pneumonia Vaccine Expansion

Fineline Cube Feb 17, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced a strategic partnership with...

Company Deals Medical Device

Shanghai-Based REMD Raises Series A+ Funding for Electroporation Device Expansion

Fineline Cube Feb 17, 2023

Shanghai-based REMD, a leading manufacturer of irreversible electroporation devices, has reportedly raised over RMB 100...

Company Drug

NMPA Approves Keverprazan for Duodenal Ulcers and Reflux Esophagitis

Fineline Cube Feb 17, 2023

The National Medical Products Administration (NMPA) has granted approval to Jiangsu Carephar Pharmaceutical Co., Ltd’s...

Company

Organon Reports Q4 and Full-Year 2022 Financials with Revenue Declines

Fineline Cube Feb 17, 2023

US-based Organon Inc. (NYSE: OGN) has released its Q4 and full-year 2022 financial results. Global...

Company Deals Digital R&D

WinHealth Pharma Taps Baidu’s ERNIE Bot for Rare Disease Services

Fineline Cube Feb 16, 2023

China-based Hong Kong WinHealth Pharma Group Ltd’s Bo’Ao Winhealth Rare Disease Medical Center has accessed...

Company

Eppendorf to Start Construction on New Shanghai Production Site

Fineline Cube Feb 16, 2023

Germany-based life sciences service provider Eppendorf is set to begin work on a new production...

Company Deals

InnoCare Regains Rights to Orelabrutinib as Biogen Terminates Licensing Agreement

Fineline Cube Feb 16, 2023

Beijing InnoCare Pharma Tech Co., (HKG: 9969), a China-based biotech focusing on cancer and autoimmune...

Company Drug

AIM Vaccine Gains Approvals for COVID-19 mRNA Vaccine Trials in Pakistan

Fineline Cube Feb 16, 2023

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving separate approvals in Pakistan to...

Company Drug

Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis

Fineline Cube Feb 16, 2023

China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III...

Company Drug

Frontera Therapeutics Initiates FT-002 Clinical Study for X-Linked Retinitis Pigmentosa

Fineline Cube Feb 16, 2023

Sino-US gene therapy specialist Frontera Therapeutics has announced the first patient dosing in a clinical...

Company Drug

Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma

Fineline Cube Feb 16, 2023

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug...

Company Drug

Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases

Fineline Cube Feb 16, 2023

China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...

Company Drug

CDE Accepts Clinical Trial Filing for Ranok’s First-in-Class BRD4 Degradation Drug RNK05047

Fineline Cube Feb 16, 2023

The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047,...

Posts pagination

1 … 580 581 582 … 684

Recent updates

  • Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets
  • Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor
  • Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction
  • Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways
  • Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Company Drug

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.